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This work describes an analytical platform based on semi-high-resolution antileishmanial
profiling combined with hyphenation of high-performance liquid chromatography –
high-resolution mass spectrometry – solid-phase extraction – nuclear magnetic
resonance spectroscopy, i.e., semiHR-antileishmanial assay/HPLC-HRMS-SPE-NMR.
The platform enables fast pinpointing of HPLC peaks representing Leishmania tropica
inhibitors in complex matrices, with subsequent structural identification of targeted
inhibitors. Active analytes were cumulatively trapped on SPE cartridges and the
structures elucidated by analysis of NMR spectra obtained in the HPLC-HRMS-
SPE-NMR mode. This led to the identification of six known compounds 2,4,6-
trihydroxyacetophenone-2-O-β-D-glucopyranoside (1), lalioside (2), luteolin-4′-O-β-D-
glucopyranoside (3), apigenin-4′-O-β-D-glucopyranoside (4), luteolin (5), and apigenin
(6). IC50 of the active compounds were determined with luteolin being the most potent
inhibitor with an IC50 value of 4.15 µg/ml. The platform proved to be an efficient method
for the identification of L. tropica inhibitors.
Keywords: Leishmania tropica, Lawsonia inermis, leishmaniasis, semi-high-resolution inhibition profile, HPLC-
HRMS-SPE-NMR
INTRODUCTION
Leishmaniasis, caused by parasites belonging to the genus Leishmania (Family Trypanosomatidae),
is a major public health problem in tropical and sub-tropical regions. The parasite is transmitted
by the sand fly vector, with dogs, sheep, rats, horses, and cats being common animal hosts of
leishmaniasis (Pearson and Sousa, 1996; Markle and Makboul, 2004). WHO has reported that
people from 98 countries – covering five continents – are at high risk of contracting leishmaniasis,
and it is estimated that approximately 12 million people are currently infected (Alvar et al.,
2012). Cutaneous leishmaniasis is caused by different Leishmania species, e.g., Leishmania tropica,
Leishmania major, Leishmania amazonensis, and Leishmania braziliensis. In Pakistan, L. tropica
is the main cause of cutaneous leishmaniasis (Rowland et al., 1999; Brooker et al., 2004). First
line therapy for cutaneous leishmaniasis in Europe, Asia, and Africa is pentavalent antimonials,
i.e., sodium stibogluconate and meglumine antimoniate (Markle and Makboul, 2004). However,
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antimonials have severe side effects like myalgia, pancreatitis,
cardiac arrhythmia, hepatitis, and accumulation of the drug in
liver and spleen. Thus, there is an urgent need for new chemical
entities for non-toxic and effective treatment of leishmaniasis
(Brooker et al., 2004; Markle and Makboul, 2004).
Lawsonia inermis L. is commonly known as Henna or
Mehndi (Family Lythraceae) (Kumar et al., 2005). It is native
to Northern Africa and South-western Asia, and is cultivated
in many tropical and sub-tropical regions (Cartwright-Jones,
2006). In Pakistan, it is widely found in the Dera Ismail khan
and Bannu districts of the Khyber Pakhtunkhwa province.
L. inermis is extensively used for different medicinal purposes,
and possess a variety of biological and pharmacological activities,
including antioxidant (Dasgupta et al., 2003), antibacterial (Ali
et al., 2001), antifungal (Singh and Pandey, 1989), antiviral
(Khan et al., 1991), antiparasitic (Okpeton et al., 2004),
analgesic (Mohsin et al., 1989), cytotoxic (Ali and Grever,
1998), antidiabetic (Arayne et al., 2007), antileishmanial (Iqbal
et al., 2016a,b) and protein glycation inhibitory activity (Sultana
et al., 2009). L. inermis is chemically well investigated (Semwal
et al., 2014), and more than 135 compounds have been
reported from the genus. This includes phenolic compounds
[flavonoids (Liou et al., 2013), naphthalenes (Hsouna et al., 2011),
naphthoquinones (Almeida et al., 2012), coumarins (Chaudhary
et al., 2010), alkylphenones (Hsouna et al., 2011)], terpenes
[volatile terpenes (Hema et al., 2010), non-volatile terpenes (Liou
et al., 2013)], aliphatic hydrocarbons, and alkaloids (Iqbal et al.,
2016b).
A major bottleneck in our ongoing search for antiparasitic
constituents from plants (Sairafianpour et al., 2002; Ziegler
et al., 2002; Pedersen et al., 2009) has been the traditional
time-consuming bioassay-guided isolation of the antileishmanial
compounds. This urged us to implement new bioanalytical
technologies for faster analyses targeting the bioactive
constituents. Hyphenation of separation techniques,
spectroscopic methods, and bioassays has in recent years
proven to be an efficient strategy for this purpose (Van
Beek et al., 2009). While the commonly used hyphenation
of high-performance liquid chromatography coupled with
high-resolution mass spectrometry (HPLC-HRMS) is a fast
and sensitive technique, it has several limitations when
it comes to full structural elucidation of complex natural
products. Especially promising is therefore the additional
hyphenation of HPLC and HPLC-HRMS with solid-phase
extraction and nuclear magnetic resonance spectroscopy, i.e.,
HPLC-(HRMS)-SPE-NMR (Lambert et al., 2005; Johansen
et al., 2011), which allows full structural identification of
complex natural products directly from crude extracts. As
HPLC-HRMS-SPE-NMR only allows for chemical analysis,
the recent combination with semi-high-resolution and/or
high-resolution bioactivity profiling, i.e., microfractionation
in microplates followed by bioassaying to yield a semi-high or
high-resolution inhibition profile, is one of the most promising
technological developments within bioanalytical plant research.
The resulting HR-bioassay/HPLC-HRMS-SPE-NMR technology
platform has already proven effective for fast identification of
α-glucosidase inhibitors (Schmidt et al., 2012, 2014; Kongstad
et al., 2015; Wubshet et al., 2015), aldose reductase inhibitors
(Tahtah et al., 2015), α-amylase inhibitors (Okutan et al.,
2014), and radical scavengers (Wiese et al., 2013; Wubshet
et al., 2013; Liu et al., 2015) directly from crude plant extracts.
However, the current work is the first example of semi-high-
resolution antileishmanial inhibition profiling coupled with
HPLC-HRMS-SPE-NMR.
MATERIALS AND METHODS
Chemicals
Fetal bovine serum (FBS), dimethyl sulfoxide (DMSO), RPMI-
1640 medium, Amphotericin B, penicillin, streptomycin, formic
acid, analytical grade HPLC solvents (chloroform, methanol,
ethyl acetate, n-hexane, acetone), and methanol-d4 (99.8 atom
% of deuterium) were purchased from Sigma-Aldrich (St. Louis,
MO, United States), whereas silica gel 60 0.063–0.200 mm
(70–230 mesh ASTM) was purchased from MERCK (Darmstadt,
Germany). Water used for HPLC was purified by deionization
and 0.22 µm membrane filtration (Millipore, Billerica, MA,
United States).
Collection of Plant Material and
Preparation of Crude Extract
Leaves of Lawsonia inermis L. were collected from the territory
of Dera Ismail Khan, Khyber Pakhtunkhwa (KPK), Pakistan
in August and September 2014. Identification was performed
by Dr. Siraj-ud-Din, Department of Botany, and a voucher
specimen [accession number: Bot, 200101 (pup)] was deposited
at Department of Botany, University of Peshawar (UOP), KPK.
The leaves were washed with distilled water before drying in the
shade at temperatures below 35◦C. The leaves were stored in a
cool dark place until use. Ground material of L. inermis (leaves,
1 kg) was extracted with methanol (2 L) for 1 week with regular
stirring. The extract was filtered and concentrated in vacuo to
afford 500 g of an oily extract.
Preparative-Scale Fractionation
The crude leaves extract (250 g) was fractionated by means
of silica gel column chromatography (100 cm × 50 mm i.d
column, silica gel 60 0.063–0.200 mm from MERCK (Darmstadt),
Germany). A gradient elution was used starting with n-hexane-
chloroform (99:1) with 20% step-wise increments to 100%
chloroform, followed by 20% increments of ethyl acetate, and
subsequent 20% increments of methanol to 100% methanol. Each
of the increments constituted 500 mL solvent, which yielded 89
fractions. Based on TLC, fractions 1–5 were pooled (fraction
F1, 6 g), fractions 6–25 (F2, 9.5 g), fractions 26–40 (F3, 3.5 g),
fractions 41–45 (F4, 5 g), fractions 46–65 (F5, 10 g), fractions
66–80 (F6, 6 g), and fractions 81–89 (F7, 8.5 g). Fraction F1–F7
was subjected for in vitro antileishmanial activity, vide infra.
In Vitro Antileishmanial Activity
In vitro antileishmanial activity of L. inermis fractions were
performed with clinically isolated L. tropica promastigotes
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(KWH23, Recently Pakistani clinically isolated strain, UOP,
Pakistan). The in vitro antileishmanial growth inhibition assay
was adopted from Iqbal et al. (2016b). Promastigotes of L. tropica
were cultured in RPMI-1640 medium containing 10% FBS,
200 U/mL of penicillin, and 0.2 mg/mL of streptomycin.
The parasites were cultured at 26◦C for 4 days in an
incubator (Gallenkamp, Size 1, United Kingdom), where after
promastigotes were harvested in sterile tubes. The number of
promastigotes was measured by transferring 5–10 µL to a
haemocytometer (Reichert Technologies, Depew, NY, United
States), and counting the number of promastigotes under upright
microscope (CX31, Olympus, Tokyo, Japan). The viable cell
count was calculated using the formula:
Viable cell count
(
live cells/mL
) =
Number of live cells counted
Number of large corner squares counted
× Dilution× 10,000
The harvested promastigotes were subsequently centrifuge at 4◦C
at 2000 rpm for 10 min, the supernatant removed, and the pellet
reconstituted in fresh RPMI-1640 medium with 10% FBS to
obtain a concentration of 1.4× 106 promastigotes/mL which was
distributed in a 96 well culture plate (180 µL each) and incubated
for 2 days at 26◦C with fractions of L. inermis.
The percentage inhibition of parasite growth was calculated
as the mean of three replicate measurements with standard
deviation using the equation:
Percentage inhibition =
count of control promastigotes− count of treated promastigotes
count of control promastigotes× 100
IC50 values were determined by non-linear regression analysis
using Graph Pad Prism 6 software.
Preparative-Scale Fractionation of F5
An injection solution of 0.1 g/mL of fraction F5 was subjected
to preparative-scale RP-HPLC using an Agilent 1100 system
equipped with two preparative solvent delivery units, a multiple
wavelength detector, an autosampler, and a fraction collector.
Separation was performed using a 250 mm × 21.2 mm
i.d. Phenomenex Luna C18 column with 5 µm particle size
(Phenomenex, Torrance, CA, United States) operated at room
temperature. The aqueous eluent (A) consisted of water–
acetonitrile (95:5), and the organic eluent (B) consisted of water–
acetonitrile (5:95) both acidified with 0.1% formic acid. The
eluent flow rate was maintained at 20 mL/min. Repeated injection
(3 × 900 µL) of the above solution was followed by a gradient
elution profile as follows: 0 min, 10% B; 40 min, 40% B; 45 min,
100% B; 55 min, 100% B; 56 min, 10% B. This afforded 27.1 mg
of subfraction 1, 10.9 mg of subfraction 2, 9.3 mg of subfraction
3, 8.3 mg of subfraction 4, 15.2 mg of subfraction 5, 10.0 mg of
subfraction 6, 10.3 mg of subfraction 7, 6.8 mg of subfraction
8, 21.1 mg of subfraction 9, 5.3 mg of subfraction 10, 6.9 mg of
subfraction 11, 5.3 mg of subfraction 12, 3.4 mg of subfraction
13, 2.5 mg of subfraction 14, 4.4 mg of subfraction 15, 96.6 mg of
subfraction 16, 35.1 mg of subfraction 17, 3.9 mg of subfraction
18, 6.3 mg of subfraction 19, and 3.7 mg of subfraction 20. All
collected subfractions were concentrated under reduced pressure
at 45◦C in rotary evaporator. Initially, the subfractions were
reconstituted in 0.1% DMSO in order to assess the IC50 values in
the in vitro antileishmanial growth inhibition assay, vide supra.
HPLC-HRMS-SPE-NMR
The HPLC-HRMS-SPE-NMR system consisted of an Agilent
1200 chromatograph comprising of a quaternary pump,
degasser, thermostated column compartment, auto sampler, and
photodiode array detector (Santa Clara, CA, United States), a
Bruker microOTOF-Q II mass spectrometer (Bruker Daltonik,
Bremen, Germany) equipped with an electrospray ionization
source and operated via a 1:99 flow splitter, a Knauer Smartline
K120 pump for post-column dilution (Knauer, Berlin, Germany),
a Spark Holland Prospekt2 SPE unit (Spark Holland, Emmen,
Netherlands), a Gilson 215 liquid handler equipped with a
1 mm needle for automated filling of 1.7 mm NMR tubes,
and a Bruker Avance III 600 MHz NMR spectrometer (1H
operating frequency 600.13 MHz) equipped with a Bruker
Sample Jet sample changer and a cryogenically cooled gradient
inverse triple-resonance 1.7 mm TCI probe-head (Bruker
Biospin, Rheinstetten, Germany). Mass spectra were acquired
in positive and negative ion modes, using drying temperature
of 200◦C, capillary voltage of −4100 and +4000 V for positive
and negative ion modes, respectively, nebulizer pressure of 2.0
bar, and drying gas flow of 7 L/min. The negative ion mode
HPLC-HRMS analysis was performed in a different experiment
using identical chromatographic condition. A solution of
sodium formate clusters was injected in the beginning of each
run to enable internal mass calibration. Chromatographic
separation was acquired on a Phenomenex Luna C18(2) column
(150 mm × 4.6 mm, 3 µm, 100 Å; Phenomenex, Torrance, CA,
United States) maintained at 40◦C, using water–acetonitrile
(95:5) (eluent A) and acetonitrile–water (95:5) (eluent B), both
acidified with 0.1% formic acid. At a flow rate of 0.5 mL/min
the following gradient elution profile was used: 0 min, 10% B;
40 min, 40% B; 45 min, 100% B; 55 min, 100% B; 56 min, 10%
B. Cumulative SPE trapping of peaks 1–9 of L. inermis fraction
F5 was performed after 10 consecutive separations. The HPLC
eluate was diluted with Milli-Q water at a flow rate of 1.5 mL/min
prior to trapping on 10 mm × 2 mm i.d. resin GP (general
purpose, 5–15 µm, spherical shape, polydivinyl-benzene phase)
SPE cartridges from Spark Holland (Emmen, Netherlands),
and analytes were trapped using absorption thresholds (280
and 330 nm). SPE cartridges were conditioned with 1000 µL
of acetonitrile at 6 mL/min and equilibrated with 500 µL of
Milli-Q water at 1 mL/min prior to trapping. Loaded cartridges
were dried with pressurized nitrogen gas for 45 min each prior
to elution with methanol-d4. Separations were controlled by
Bruker HyStar version 3.2 software, automated filling of NMR
tubes was controlled by Prep Gilson ST version 1.2 software, and
automated NMR acquisition was controlled by Bruker IconNMR
version 4.2 software. NMR data processing was performed using
Bruker Topspin version 3.2 software.
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NMR Experiments
All NMR spectra were recorded in methanol-d4 at 300 K. 1H
and 13C chemical shifts were referenced to the residual solvent
signal (δ 3.31 and 49.00, respectively). One dimensional 1H
NMR spectra were with 30◦ pulses, 3.66 s interpulse intervals,
64k data points, and multiplied with an exponential function
corresponding to line-broadening of 0.3 Hz prior to Fourier
transform. Phase-sensitive DQF-COSY spectra were recorded
using a gradient-based pulse sequence with a 20 ppm spectral
width and 2k × 256 data points (processed with forward
linear prediction to 1k data points). Multiplicity-edited HSQC
spectra were acquired with the following parameters: spectral
width 20 ppm for 1H and 165 ppm for 13C, 2k × 256
data points (processed with forward linear prediction to 1k
data points), and 2.0 s relaxation delay. HMBC spectra were
optimized for nJC,H = 10 Hz and acquired using the following
parameters: spectral width 20 ppm for 1H and 222 ppm
for 13C, 2k × 128 data points (processed with forward
linear prediction to 1k data points), and 1.5 s relaxation
delay.
RESULTS
The current work describes the use of HPLC-HRMS-SPE-
NMR for dereplication of metabolites in extract of Lawsonia
inermis leaves – in combination with semi-high-resolution
antileishmanial profiling. Initially, crude methanol extract was
tested for its ability to inhibit extracellular promastigotes of
L. tropica at concentrations of 100, 50, 25, and 10 mg/ml, which
resulted in 100% inhibition at all concentrations. The crude
methanol extract was subsequently subjected to preparative-
scale column chromatography for separation into seven fractions
(F1–F7). These fractions were tested for their ability to inhibit
extracellular promastigotes, and as seen in Table 1, Fraction 5
showed the strongest antileishmanial activity.
Fraction 5 was selected for semi-high-resolution
antileishmanial screening with the eluate from 10 to 40 min
being separated into 20 sub-fractions in 96-well microplates.
The eluate was evaporated, and the dried material in each well
was redissolved in DMSO to make stock and working solutions.
These solutions were assayed for their in vitro antileishmanial
activity toward extracellular promastigotes. The active major
constituents of subfractions 5, 7, 10, and 13 were identified by
HPLC-HRMS-SPE-NMR directly from the crude extract and the
IC50 values of the identified, active metabolites were determined.
DISCUSSION
HPLC-HRMS-SPE-NMR
The major metabolites of the active fractions (peaks 2, 4, 5, 7, and
9), together with additional four peaks, were subjected to HPLC-
HRMS-SPE-NMR analysis (Figure 1). Detailed HRMS and NMR
analysis resulted in identification of six known compounds 1–6
(Figure 2) corresponding to peaks 1, 2, 4, 5, 7, and 9, while for
peaks 3, 6, and 8, the quality of the NMR data did not allow
TABLE 1 | IC50 values of Lawsonia inermis leaves extract and fractions.
Sample Sample concentrations (mg/ml) Percent inhibition
F1 10 6.25 ± 0.57
25 18.75 ± 1.00
50 31.25 ± 0.57
100 37.5 ± 0.57
F2 10 7.50 ± 0.00
25 22.5 ± 0.57
50 30.0 ± 1.00
100 35.0 ± 0.00
F3 10 1.25 ± 0.57
25 6.25 ± 0.00
50 25.0 ± 0.57
100 27.5 ± 0.57
F4 10 6.25 ± 0.57
25 7.50 ± 0.57
50 12.5 ± 0.57
100 18.75 ± 0.57
F5 10 98.0 ± 0.57
25 98.0 ± 0.57
50 99.0 ± 0.00
100 100 ± 0.00
F6 10 12.5 ± 0.57
25 25.0 ± 1.15
50 37.5 ± 0.57
100 43.75 ± 0.57
F7 10 0.00 ± 0.00
25 12.5 ± 0.57
50 18.75 ± 0.00
100 25.0 ± 0.57
Data represent mean percent inhibition ± SD of three replicates.
for full structure elucidation. 1H NMR and HRMS data of 1–6
obtained in the HPLC-HRMS-SPE-NMR mode is provided in the
compound summary paragraph.
The known compounds were identified by comparison
of their spectral data with those reported in the literature
as 2,4,6-trihydroxyacetophenone-2-O-β-D-glucopyranoside (1)
(Lee et al., 1996), lalioside (2) (Takeda and Fatope, 1988),
luteolin-4′-O-β-D-glucopyranoside (3) (Lee et al., 2002), apigenin
4′-O-β-D-glucopyranoside (4) (Ding et al., 2004), luteolin (5)
(Scognamiglio et al., 2014), and apigenin (6) (Miyazawa and
Hisama, 2003) and confirmed by 2D NMR analysis.
Antileishmanial Activity
In our work, F5 was subjected to prep HPLC for time slice
based fractionation. It results in 20 sub-fractions which were
further analyzed by extracellular promastigotes in which four
sub-fractions showed promising inhibitory activity as shown in
Table 2. After observation of their significant antileishmanial
activity in the sub-fraction screening, lalioside (2), luteolin-4′-
O-β-D-glucopyranoside (3), apigenin 4′-O-β-D-glucopyranoside
(4), luteolin (5), and apigenin (6) were isolated by preparative-
and analytical-scale HPLC, and the materials were used for
assessing IC50 values in antileishmanial activity assay.
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FIGURE 1 | HPLC chromatogram of Lawsonia inermis L. leaves F5 extract at 280 nm acquired in the HPLC-HRMS-SPE-NMR mode.
FIGURE 2 | Compounds identified from Lawsonia inermis L. leaves extract.
TABLE 2 | IC50 values of major metabolites in active Lawsonia inermis L.
subfractions.
Compound (subfraction) IC50 value (µg/mL)
Lalioside (SF 5) 5.02
Luteolin-4′-O-β-D-glucopyranoside (SF 7) 10.27
Apigenin-4′-O-β-D-glucopyranoside (SF 7) 9.51
Luteolin (SF 10) 4.15
Apigenin (SF 13) 8.30
Amphotericin B (Positive control) 1.17
Data represent mean IC50 values with 95% confidence intervals.
This is in agreement with previously observed inhibition of
L. tropica by crude extract of different L. inermis plant parts
(Iqbal et al., 2016b). Tasdemir et al. (2006) have previously
investigated the structure-activity relationship of flavonoids,
including luteolin (5) and apigenin (6). It was found that a
minimum of two hydroxy substituents on the A ring, preferably
on position 5, 7, and 8, greatly increased the antileishmanial
potential. Furthermore, the double bond between C-2 and
C-3 proved to be important for the activity. Both luteolin
(5) and apigenin (6) are di-substituted on the ‘A’ ring on
positions 5 and 7 and both having the important double bond
12,3 accounting for the IC50 values of 4.15 and 8.30 µg/mL,
respectively, with the differences in the antileishmanial potential
attributes to the different substitution pattern on the B ring.
Interestingly, the 4′-O-β-D-glucosides of 5 and 6 (10.27 and
9.51 µg/mL, 3 and 4, respectively) showed a markedly decreased
inhibitory effect against extracellular promastigotes. This is in
line with previous reports that glucosylation on the A ring
have similar effects (Tasdemir et al., 2006). Lalioside (2), a
tetra-substituted acetophenone glucoside, showed promising
inhibitory effects with an IC50 value of 5.02 µg/mL while the tri-
substituted acetophenone glucoside (1) did not show noteworthy
antileishmanial potential in the semi-high-resolution screening,
indicating the importance of the C-3 hydroxyl substituent. While
both luteolin (5) and apigenin (6) have previously been shown
to possess activity against L. donovani (0.8 and 1.8 µg/mL,
respectively) (Tasdemir et al., 2006) this is the first report of
their in vitro activity against L. tropica and the first time lalioside
(2), luteolin-4′-O-β-D-glucopyranoside (3), and apigenin-4′-O-
β-D-glucopyranoside (4) are reported against any Leishmania
species.
CONCLUSION
In conclusion, luteolin and lalioside are potent inhibitors while
apigenin, apigenin-4′-O-β-D-glucopyranoside, and luteolin-4′-
O-β-D-glucopyranoside have moderate inhibitory effect on
extracellular promastigotes of L. tropica. Further studies on
identified compounds of Lawsonia Inermis are planned to
investigate specificity and structure-activity relationship.
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2,4,6-Trihydroxyacetophenone-2-O-β-D-glucopyranoside
(1): 1H NMR (CD3OD, 600 MHz) δ 6.18 (1H, d, J = 1.8 Hz,
H-3), 5.95 (1H, t, J = 1.8 Hz, H-5), 5.02 (1H, d, J = 7.8 Hz, H-1′),
3.93, d, J = 12.1 Hz H-6′A), 3.73 (dd, J = 12.1, 5.5 Hz, H-6′B),
3.53 (1H, dd, J = 9.2, 7.8 Hz, H-2′), 3.48 (2H, m, H-3′, H-5′), 3.41
(1H, t, J = 9.5 Hz, H-3′), 2.69 (3H, s, Me); (+) HRESIMS m/z
331.1022 [M+H]+ (calcd for C14H19O9+,1M 0.4 ppm).
Lalioside (2): 1H NMR (CD3OD, 600 MHz) δ 5.90 (1H, s,
H-5), 4.53 (1H, d, J = 7.8 Hz, H-1′), 3.84, dd, J = 12.1, 2.3 Hz,
H-6′A), 3.76 (dd, J = 12.1, 4.4 Hz, H-6′B), 3.4-3.51 (3H, m, H-3′,
H-4′, H-5′), 3.45 (1H, m, H-2′), 2.63 (3H, s, Me); (+) HRESIMS
m/z 347.0976 [M+H]+ (calcd for C14H19O10+,1M−0.8 ppm).
Luteolin-4′-O-β-D-glucopyranoside (3): 1H NMR (CD3OD,
600 MHz) δ 7.43 (2H, m, H-2′, H-6′), 7.30 (1H, d, J = 8.3 Hz,
H-5′), 6.59 (1H, s, H-3), 6.44 (1H, brs, H-8), 6.20 (1H, brs, H-6),
4.94 (1H, d, J = 7.6 Hz, H-1′′), 3.93 (1H, dd, J = 12.2, 1.9 Hz, H-
6′′A), 3.74 (1H, dd, J = 12.2, 5.5 Hz, H-6′′B), 3.54 (1H, m, H-2′′),
3.50 (2H, m, H-3′′, H-5′′), 3.43 (1H, m, H-4′′); (+) HRESIMS m/z
449.1084 [M+H]+ (calcd for C21H21O11+,1M−1.3 ppm).
Apigenin-4′-O-β-D-glucopyranoside (4): 1H NMR (CD3OD,
600 MHz) δ 7.95 (2H, d, J = 8.9 Hz, H-2′/H-6′), 7.25 (2H, d,
J = 8.9 Hz, H-3′/H-5′), 6.66 (1H, s, H-3), 6.48 (1H, d, J = 2.1 Hz,
H-8), 6.26 (1H, d, J = 2.1 Hz, H-6), 5.04 (1H, d, J = 7.6 Hz,
H-1′′), 3.92 (1H, dd, J = 12.1, 2.1 Hz, H-6′′A), 3.72 (1H, dd,
J = 12.1, 5.6 Hz, H-6′′B), 3.50 (3H, m, H-2′′, H-3′′, H-5′′), 3.43
(1H, m, H-4′′); (+) HRESIMS m/z 433.1128 [M+H]+ (calcd for
C20H21O10+,1M 0.2 ppm).
Luteolin (5) : 1H NMR (CD3OD, 600 MHz) δ 7.39 (1H, dd,
J = 8.6, 2.3 Hz, H-6′), 7.38 (1H, d, J = 2.3 Hz, H-2′), 6.90 (1H,
d, J = 8.6 Hz, H-5′), 6.55 (1H, s, H-3), 6.45 (1H, d, J = 2.1 Hz,
H-8), 6.22 (1H, d, J = 2.1 Hz, H-6); (+) HRESIMS m/z 287.0552
[M+H]+ (calcd for C15H11O6+,1M−0.8 ppm).
Apigenin (6) : 1H NMR (CD3OD, 600 MHz) δ 7.86 (2H, d,
J = 8.9 Hz, H-2′/H-6′), 6.94 (2H, d, J = 8.9 Hz, H-3′/H-5′),
6.60 (1H, s, H-3), 6.47 (1H, d, J = 2.1 Hz, H-8), 6.22 (1H, d,
J = 2.1 Hz, H-6); (+) HRESIMS m/z 271.0606 [M+H]+ (calcd
for C15H11O5+,1M−1.9 ppm).
REFERENCES
Ali, M., and Grever, M. R. (1998). A cytotoxic napthoquinone from Lawsonia
inermis. Fitoterapia 69, 181–183.
Ali, N. A., Julich, W. D., Kusnick, C., and Lindequist, U. (2001). Screening
of Yemeni medicinal plants for antibacterial and cytotoxic activities.
J. Ethnopharmacol. 74, 173–179. doi: 10.1016/S0378-8741(00)00364-0
Almeida, P. J., Borrego, L., Pulido-Melian, E., and Gonzalez-Diaz, O. (2012).
Quantification of p-phenylenediamine and 2-hydroxy-1,4-naphthoquinone in
henna tattoos. Contact. Dermatitis 66, 33–37. doi: 10.1111/j.1600-0536.2011.
01992.x
Alvar, J., Velez, I. D., Bern, C., Herrero, M., Desjeux, P., Cano, J., et al. (2012).
Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE
7:e35671. doi: 10.1371/journal.pone.0035671
Arayne, M. S., Sultana, N., Mirza, A. Z., Zuberi, M. H., and Siddiqui, F. A. (2007).
In vitro hypoglycemic activity of methanolic extract of some indigenous plants.
Pak. J. Pharm. Sci. 20, 268–273.
Brooker, S., Mohammed, N., Adil, K., Agha, S., Reithinger, R., Rowland, M., et al.
(2004). Leishmaniasis in refugee and local Pakistan populations. Emerg. Infect.
Dis. 10, 1681–1684. doi: 10.3201/eid1009.040179
Cartwright-Jones, C. (2006). Developing Guidelineson Henna: A Geographical
Approach. Masters’ dissertation, Kent State University, Kent, OH.
Chaudhary, G., Goyal, S., and Poonia, P. (2010). Lawsonia inermis Linnaeus: a
phytopharmacological review. Int. J. Pharm. Sci. Drug. Res. 2, 91–98.
Dasgupta, T., Rao, A. R., and Yadava, P. K. (2003). Modulatory effect of
henna leaf (Lawsonia inermis) on drug metabolizing phase I and Phase II
enzymes, antioxidant enzymes, lipid peroxidation and chemically induced skin
and forestomach papillomagenesis in mice. Mol. Cell. Biochem. 245, 11–22.
doi: 10.1023/A:1022853007710
Ding, H. Y., Chan, Y. Y., Chang, W. L., and Lin, H. C. (2004). Flavonoids from the
flowers of Pueraria lobata. J. Chin. Chem. Soc. 51, 1425–1428. doi: 10.1002/jccs.
200400210
Hema, R., Kumaravel, S., Gomathi, S., and Sivasubramaniam, C. (2010). Gas
chromatography-Mass spectroscopic analysis of Lasonia inermis leaves. Life Sci.
J. 7, 48–50.
Hsouna, A. B., Trigui, M., Culioli, G., Blache, Y., and Jaoua, S. (2011). Antioxidants
constituents from Lawsonia inermis leaves: Isolation, structure elucidation and
antioxidative capacity. Food Chem. 125, 193–200. doi: 10.1016/j.foodchem.
2010.08.060
Iqbal, K., Iqbal, J., and Afreen, M. S. (2016a). Comparative study on antileishmanial
and cytotoxic activity of Lawsonia inermis bark and Aloe Vera leaves. Int. J. Biol.
Pharm. Allied. Sci. 5, 1490–1500.
Iqbal, K., Iqbal, J., Umair, M., Farooq, U., Iqbal, M. M., Qamar, S., et al. (2016b).
Anti-leishmanial and cytotoxic activities of extracts from three Pakistani Plants.
Trop. J. Pharm. Res. 15, 2113–2119. doi: 10.4314/tjpr.v15i10.9
Johansen, K. T., Wubshet, S. G., Nyberg, N. T., and Jaroszewski, J. W. (2011).
From retrospective assessment to prospective decisions in natural product
isolation: HPLC-SPE-NMR analysis of Carthamus oxyacantha. J. Nat. Prod. 74,
2454–2461. doi: 10.1021/np200780m
Khan, M. M., Ali, A., Jain, D. C., Bhakuni, R. S., Zaim, M., and Thakur, R. S. (1991).
Occurrence of some antiviral sterols in Artemisia annua. Plant Sci. 75, 161–165.
doi: 10.1016/0168-9452(91)90230-6
Kongstad, K. T., Özdemir, C., Barzak, A., Wubshet, S. G., and Staerk, D. (2015).
Combined use of high-resolution α-glucosidase inhibition profiling and high-
performance liquid chromatography-high-resolution mass spectrometry-solid-
phase extraction-nuclear magnetic resonance spectroscopy for investigation
of antidiabetic principles in crude plant extracts. J. Agric. Food. Chem. 63,
2257–2263. doi: 10.1021/jf506297k
Kumar, S., Singh, Y. V., and Singh, M. (2005). Agro-History, Uses, Ecology and
Distribution of Henna (Lawsonia inermis L. syn. Alba Lam). Henna: Cultivation,
Improvement, and Trade. Jodhpur: Central Arid Zone Research Institute,
11–12.
Lambert, M., Staerk, D., Hansen, S. H., and Jaroszewski, J. W. (2005). HPLC-SPE-
NMR hyphenation in natural products research: optimization of analysis of
Frontiers in Pharmacology | www.frontiersin.org 6 May 2017 | Volume 8 | Article 337
fphar-08-00337 May 29, 2017 Time: 17:20 # 7
Iqbal et al. Antileishmanial Compounds from Lawsonia inermis
Croton membranaceus extract. Magn. Reson. Chem. 43, 771–775. doi: 10.1002/
mrc.1613
Lee, K. R., Hong, S. W., Kwak, J. H., Pyo, S. P., and Jee, O. P. (1996). Phenolic
constituents from the Aerial parts of Artemisia stolonifera. Arch. Pharm. Res.
19, 231–234. doi: 10.1007/BF02976896
Lee, M. H., Son, Y. K., and Han, Y. N. (2002). Tissue factor inhibitory flavonoids
from the fruits of Chaenomeles sinensis. Arch. Pharm. Res. 25, 842–850.
doi: 10.1007/BF02977002
Liou, J. R., El-Shazly, M., Du, Y. C., Tseng, C. N., Hwang, T. L., Chuang, Y. L., et al.
(2013). 1,5-Diphenylpent-3-en-1-ynes and methyl naphthalene carboxylates
from Lawsonia inermis and their anti-inflammatory activity. Phytochemistry 88,
67–73. doi: 10.1016/j.phytochem.2012.11.010
Liu, B., Kongstad, K. T., Qinglei, S., Nyberg, N. T., Jäger, A. K., and Staerk, D.
(2015). Dual high-resolution α-glucosidase and radical scavenging profiling
combined with HPLC-HRMS-SPE-NMR for identification of minor and major
constituents directly from the crude extract of Pueraria lobata. J. Nat. Prod. 78,
294–300. doi: 10.1021/np5009416
Markle, W. H., and Makboul, K. (2004). Cutaneous leishmaniasis recognition and
treatment. Am. Fam. Physician 69, 455–460.
Miyazawa, M., and Hisama, M. (2003). Antimutagenic activity of flavonoids
from Chrysanthemum morifolium. Biosci. Biotechnol. Biochem. 67, 2091–2099.
doi: 10.1271/bbb.67.2091
Mohsin, A., Shah, A. H., Al-Yahya, M. A., Tariq, M., Tanira, M. O., and Ageel, A. A.
(1989). Analgesic, antipyretic activity and phytochemical screening of some
plants used in traditional Arab system of medicine. Fitoterapia 60, 174–177.
Okpeton, T., Yolou, S., Gleye, C., Roblot, F., Loiseau, P., Bories, C., et al.
(2004). Antiparasitic activities of medicinal plants used in ivory Coast.
J. Ethnopharmacol. 90, 91–97. doi: 10.1016/j.jep.2003.09.029
Okutan, L., Kongstad, K. T., Jäger, A. K., and Staerk, D. (2014). High-resolution
α-amylase assay combined with high-performance liquid chromatography-
solid-phase extraction-nuclear magnetic resonance spectroscopy for expedited
identification of α-amylase inhibitors: proof of concept and α-amylase inhibitor
in cinnamon. J. Agric. Food Chem. 62, 11465–11471. doi: 10.1021/jf5047283
Pearson, R. D., and Sousa, A. D. Q. (1996). Clinical spectrum of leishmaniasis. Clin.
Infect. Dis. 22, 1–13. doi: 10.1093/clinids/22.1.1
Pedersen, M. M., Chukwujekwu, J. C., Lategan, C. A., Staden, J. V., Smith, P. J.,
and Staerk, D. (2009). Antimalarial sesquiterpene lactones from Distephanus
angulifolius. Phytochemistry 70, 601–607. doi: 10.1016/j.phytochem.2009.02.005
Rowland, M., Munir, A., Durrani, N., Noyes, H., and Reyburn, H. (1999). An
outbreak of cutaneous leishmaniasis in an Afghan refugee settlement in north-
west Pakistan. Trans. R. Soc. Trop. Med. Hyg. 93, 133–136. doi: 10.1016/S0035-
9203(99)90285-7
Sairafianpour, M., Kayser, O., Christensen, J., Asfa, M., Witt, M., Staerk, D., et al.
(2002). Leishmanicidal and antiplasmodial activity of constituents of Smirnowia
iranica. J. Nat. Prod. 65, 1754–1758. doi: 10.1021/np020244s
Schmidt, J. S., Lauridsen, M. B., Dragsted, L. O., Nielsen, J., and Staerk, D.
(2012). Development of a bioassay-coupled HPLC-SPE-ttNMR platform for
identification of α-glucosidase inhibitors in apple peel (Malus × domestica
Borkh.). Food Chem. 135, 1692–1699. doi: 10.1016/j.foodchem.2012.05.075
Schmidt, J. S., Nyberg, N. T., and Staerk, D. (2014). Assessment of constituents in
Allium by multivariate data analysis, high-resolution α-glucosidase inhibition
assay and HPLC-SPE-NMR. Food. Chem. 161, 192–198. doi: 10.1016/j.
foodchem.2014.03.062
Scognamiglio, M., Fiumano, V., Abrosca, B. D., Esposito, A., Choi, Y. H.,
Verpoortw, R., et al. (2014). Chemical interactions between plants in
Mediterranean vegetation: the influence of selected plant extracts on Aegilops
geniculata metabolome. Phytochemistry 106, 69–85. doi: 10.1016/j.phytochem.
2014.07.006
Semwal, R. B., Semwal, D. K., Combrinck, S., Cartwright-Jones, C., and Viljoen, A.
(2014). Lawsonia inermis L. (Henna): Ethnobotanical, phytochemical and
pharmacological aspects. J. Ethnopharmacol. 155, 80–103. doi: 10.1016/j.jep.
2014.05.042
Singh, V. K., and Pandey, D. K. (1989). Fungitoxic studies on bark extract
of Lawsonia inermis against ringworm fungi. Hindustan Antibiot. Bull. 31,
32–35.
Sultana, N., Chaudhary, M. I., and Khan, A. J. (2009). Protein glycation inhibitory
activities of Lawsonia inermis and its active principles. J. Enzym. Inhib. Med.
Chem. 24, 257–261. doi: 10.1080/14756360802057500
Tahtah, Y., Kongstad, K. T., Wubshet, S. G., Nyberg, N. T., Jønsson, L. H.,
Jäger, A. K., et al. (2015). Triple aldose reductase/α-glucosidase/radical
scavenging high-resolution profiling combined with high-performance liquid
chromatography-high-resolution mass spectrometry-solid-phase extraction-
nuclear magnetic resonance spectroscopy for identification of antidiabetic
constituents in crude extract of Radix Scutellariae. J. Chromatogr. A 1408,
125–132. doi: 10.1016/j.chroma.2015.07.010
Takeda, Y., and Fatope, M. O. (1988). New phenolic glucosides from Lawsonia
inermis. J. Nat. Prod. 51, 725–729. doi: 10.1021/np50058a010
Tasdemir, D., Kaiser, M., Brun, R., Yardley, V., Schmidt, T. J., Tosun, F., et al.
(2006). Antitrypanosomal and antileishmanial activities of flavonoids and their
analogues: in vitro, in vivo, structure-activity relationship, and quantitative
structure-activity relationship studies. Antimicrob. Agents Chemother. 50,
1352–1364. doi: 10.1128/AAC.50.4.1352-1364.2006
Van Beek, T., Tetala, K., Koleva, I., Dapkevicius, A., Exarchou, V., Jeurissen, S., et al.
(2009). Recent developments in the rapid analysis of plants and tracking their
bioactive constituents. Phytochemistry Rev. 8, 387–399. doi: 10.1007/s11101-
009-9125-9
Wiese, S., Wubshet, S. G., Nielsen, J., and Staerk, D. (2013). Coupling HPLC-SPE-
NMR with a microplate-based high-resolution antioxidant assay for efficient
analysis of antioxidants in food – Validation and proof-of-concept study with
caper buds. Food Chem. 141, 4010–4018. doi: 10.1016/j.foodchem.2013.06.115
Wubshet, S. G., Moresco, H. H., Tahtah, Y., Brighente, I. M., and Staerk, D.
(2015). High-resolution bioactivity profiling combined with HPLC-HRMS-
SPE-NMR: α-Glucosidase inhibitors and acetylated ellagic acid rhamnosides
from Myrcia palustris DC. (Myrtaceae). Phytochemistry 116, 246–252.
doi: 10.1016/j.phytochem.2015.04.004
Wubshet, S. G., Schmidt, J. S., Wiese, S., and Staerk, D. (2013). High-
resolution screening combined with HPLC-HRMS-SPE-NMR for identification
of potential health-promoting constituents in sea aster and searocket–new
Nordic food ingredients. J. Agric. Food Chem. 61, 8616–8623. doi: 10.1021/
jf402949y
Ziegler, H. L., Jensen, T. H., Christensen, J., Staerk, D., Hägerstrand, H., Sittie, A. A.,
et al. (2002). Possible artefacts in the in vitro determination of antimalarial
activity of natural products that incorporate into lipid bilayer: apparent
antiplasmodial activity of dehydroabietinol, a constituent of Hyptis suaveolens.
Planta Med. 68, 547–549. doi: 10.1055/s-2002-32548
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Iqbal, Iqbal, Staerk and Kongstad. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 7 May 2017 | Volume 8 | Article 337
